Literature DB >> 8827084

Matrilysin expression in the involuting rat ventral prostate.

W C Powell1, F E Domann, J M Mitchen, L M Matrisian, R B Nagle, G T Bowden.   

Abstract

Matrilysin (PUMP-1) is a member of the matrix metalloproteinase (MMP) family of extracellular matrix degrading enzymes that has been found to be overexpressed in human prostate cancer. The rat ventral prostate (RVP) following castration has been used as a model for both tissue involution and apoptosis. Northern analysis and in situ hybridization were used to determine the time course and localization of matrilysin during 8 days of RVP involution. Northern analysis revealed that the 1.2 kb matrilysin mRNA was undetectable in normal RVP. An increase in the steady-state levels of matrilysin mRNA was observed 5 days after castration, and the levels began to decline by 8 days after castration. The mRNAs for tissue inhibitor of metalloproteinase-1 and urokinase-type plasminogen activator also showed a time-dependent induction during the course of involution. Localization of matrilysin by in situ hybridization indicated that the mRNA was produced by epithelial cells of the involuting RVP. The matrilysin message was observed in a small number of glands within the whole RVP. Matrilysin protein was present in the RVP and peaked 3 days after castration. The combination of proteinase genes expressed in the RVP following castration indicate that the MMP and serine protease families of enzymes may interact during tissue remodeling of the RVP following castration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827084     DOI: 10.1002/1097-0045(199609)29:3<159::aid-pros2990290304>3.0.co;2-l

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.

Authors:  Laurie E Littlepage; Mark D Sternlicht; Nathalie Rougier; Joanna Phillips; Eugenio Gallo; Ying Yu; Kurt Williams; Audrey Brenot; Jeffrey I Gordon; Zena Werb
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

2.  Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection.

Authors:  Sukumar Pal; Amy P Schmidt; Ellena M Peterson; Carole L Wilson; Luis M de la Maza
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

3.  Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP.

Authors:  M S Maliner-Stratton; R D Klein; T S Udayakumar; R B Nagle; G T Bowden
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

4.  A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo.

Authors:  Barbara Fingleton; William C Powell; Howard C Crawford; John R Couchman; Lynn M Matrisian
Journal:  Hybridoma (Larchmt)       Date:  2007-02

5.  Multiple, temporal-specific roles for HNF6 in pancreatic endocrine and ductal differentiation.

Authors:  Hongjie Zhang; Elizabeth Tweedie Ables; Christine F Pope; M Kay Washington; Susan Hipkens; Anna L Means; Gunter Path; Jochen Seufert; Robert H Costa; Andrew B Leiter; Mark A Magnuson; Maureen Gannon
Journal:  Mech Dev       Date:  2009-09-18       Impact factor: 1.882

6.  Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression.

Authors:  Pin-Shern Chen; Yuan-Wei Shih; Hsiang-Ching Huang; Hsing-Wen Cheng
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

7.  Coordinated elevation of membrane type 1-matrix metalloproteinase and matrix metalloproteinase-2 expression in rat uterus during postpartum involution.

Authors:  Kengo Manase; Toshiaki Endo; Mitunobu Chida; Kunihiko Nagasawa; Hiroyuki Honnma; Kiyohiro Yamazaki; Yoshimitu Kitajima; Taeko Goto; Mika Kanaya; Takuhiro Hayashi; Toshihiro Mitaka; Tsuyoshi Saito
Journal:  Reprod Biol Endocrinol       Date:  2006-06-02       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.